Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)

Jang Ho Cho, Sung Hee Lim, Ho Jung An, Ki Hwan Kim, Keon Uk Park, Eun Joo Kang, Yoon Hee Choi, Mi Sun Ahn, Myung Hee Lee, Jong Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung Ju Ahn

Research output: Contribution to journalComment/debate

Abstract

The February 10, 2020, article by Cho et al, entitled “Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)” (J Clin Oncol 10.1200/JCO.19.00931), was published with an error.

Original languageEnglish
Pages (from-to)1248
Number of pages1
JournalJournal of Clinical Oncology
Volume38
Issue number11
DOIs
Publication statusPublished - 2020 Apr 10

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)'. Together they form a unique fingerprint.

  • Cite this

    Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J. M., Lee, S. H., Ahn, J. S., Park, K., & Ahn, M. J. (2020). Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931). Journal of Clinical Oncology, 38(11), 1248. https://doi.org/10.1200/JCO.20.00446